- New Brunswick, Northwest Territories and the Non-Insured
Health Benefits (NIHB) program for First Nations and Inuit
peoples will reimburse Vascepa for the reduction of
cardiovascular risk in patients with established cardiovascular
disease
TORONTO, June 22,
2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focusing on central
nervous system and cardiovascular markets, announces that it has
successfully entered into Product Listing Agreements ("PLA") with
New Brunswick, Northwest Territories and the NIHB, for the
listing and public reimbursement of Vascepa (icosapent ethyl) on
their respective Public Prescription Drug Insurance Plans. All
three PLAs are now in effect.
Under the terms of the respective PLAs, Vascepa will be
reimbursed for the secondary prevention of cardiovascular events
(cardiovascular death, non-fatal myocardial infarction, non-fatal
stroke, coronary revascularization or hospitalization for unstable
angina) in statin-treated patients with established cardiovascular
disease and elevated triglycerides.
"We are pleased to build on our agreement with the province of
Quebec to add three additional
public listings as we work to bring Vascepa to Canadians who are
battling cardiovascular disease, the number one killer worldwide,"
said Gilbert Godin, CEO of HLS. "We
continue to work with other provinces and territories to secure
coverage for Vascepa from their publicly funded drug plans and will
provide further updates on our progress as they occur."
As disclosed previously, HLS achieved public reimbursement and a
PLA in the province of Quebec in
May 2022 and has reimbursement
coverage for more than 90% of privately covered lives in
Canada that are in-label.
ABOUT VASCEPA (ICOSAPENT ETHYL)
CAPSULES
VASCEPA capsules are the first-and-only prescription treatment
comprised solely of the active ingredient, icosapent ethyl (IPE), a
unique form of eicosapentaenoic acid. VASCEPA was approved by
Health Canada and added to Health Canada's Register of Innovative
Drugs and benefits from data protection for a term of eight years,
as well as being the subject of multiple issued and pending patents
based on its unique clinical profile. HLS in-licensed the
exclusive rights to VASCEPA for the Canadian market from Amarin
Corporation (NASDAQ: AMRN).
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information visit:
www.hlstherapeutics.com
FORWARD LOOKING
INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities, expectations regarding financial
performance, and the NCIB and ASPP. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting HLS, including risks relating to the
specialty pharmaceutical industry, risks related to the regulatory
approval process, economic factors and many other factors beyond
the control of HLS. Forward-looking statements and information by
their nature are based on assumptions and involve known and unknown
risks, uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 16, 2022, and
Management's Discussion and Analysis dated May 4, 2022, both of which have been filed on
SEDAR and can be accessed at www.sedar.com. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and HLS undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.